ENSYMBI Trademark

Trademark Overview

On Wednesday, February 27, 2019, a trademark application was filed for ENSYMBI with the United States Patent and Trademark Office. The USPTO has given the ENSYMBI trademark a serial number of 88318114. The federal status of this trademark filing is ABANDONED - EXPRESS as of Thursday, March 14, 2019. This trademark is owned by Samsung Bioepis Co., Ltd.. The ENSYMBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritis
ensymbi

General Information

Serial Number88318114
Word MarkENSYMBI
Filing DateWednesday, February 27, 2019
Status601 - ABANDONED - EXPRESS
Status DateThursday, March 14, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSamsung Bioepis Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIncheon, 21987
KR

Trademark Events

Event DateEvent Description
Tuesday, March 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, March 14, 2019ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Thursday, March 14, 2019ABANDONMENT - EXPRESS MAILED
Wednesday, March 13, 2019TEAS EXPRESS ABANDONMENT RECEIVED
Saturday, March 2, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

ensymbi preparations pharmaceutical treating treatment arthritis diseases conditions cancer idiopathic enthesitis